Wilbanks Smith & Thomas Asset Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-9,367	Closed	-$344K	–	1393
2018 Q3	$344K	Sell	9,367 -7,367	-44%	-$237K	0.02%	285
2018 Q2	$586K	Buy	16,734 +10,046	+150%	+$385K	0.05%	179
2018 Q1	$311K	Buy	6,688 +1,600	+31%	+$58.6K	0.03%	254
2017 Q4	$191K	Buy	+5,088	New	+$222K	0.02%	331

Other funds holding KDNY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's KDNY Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2018, closing a stake of 9,367 shares — an estimated $344K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in KDNY in Q4 2017 and held it in 4 quarters. The position peaked at $586K in Q2 2018. 85 funds tracked by Wall St. Rank hold KDNY as of Q4 2018.

Wilbanks Smith & Thomas Asset Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Wilbanks Smith & Thomas Asset Management sold 9,367 Chinook Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $344K.
Wilbanks Smith & Thomas Asset Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2017 and held it in 4 quarters.
Wilbanks Smith & Thomas Asset Management's Chinook Therapeutics, Inc. Common Stock position peaked at $586K in Q2 2018.
85 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.